FoxO3B: A Potential Drug Target and Biomarker in Cancer (G2310)

Target Name: FOXO3B

NCBI ID: G2310

FOXO3B

FoxO3B: A Potential Drug Target and Biomarker in Cancer

Cancer is a leading cause of human mortality, with over 50% of all deaths worldwide due to cancer. The rapid development of new treatments has led to the identification of many potential drug targets. One of these targets is FoxO3B, a pseudogene that encodes a protein involved in cell growth and survival. In this article, we will discuss FoxO3B as a drug target and biomarker in cancer.

FoxO3B: Background and Characteristics

FoxO3B is a 25kDa protein that is highly conserved across various species, including humans. It is a member of the FoxO3 gene family, which is known for its role in various cellular processes, including cell growth, survival, and stress response. FoxO3B is expressed in various tissues and cells, including brain, spinal cord, heart, and organs.

FoxO3B has unique structural features that make it a potential drug target. It has a split N-terminus, which is unique among proteins with similar sequences. Additionally, it has a unique C-terminus that is rich in conserved acidic residues, which may be involved in its stability or interactions with other proteins.

Expression and Function of FoxO3B

FoxO3B is highly expressed in various tissues and cells, including brain, and is involved in various cellular processes, including cell growth, survival, and stress response. It has been shown to play a role in cell proliferation, differentiation, and survival.

FoxO3B has also been shown to be involved in various signaling pathways, including the TGF-灏? pathway. TGF-灏? is a well-known signaling pathway that is involved in cell growth, differentiation, and survival.

FoxO3B has also been shown to be involved in the Wnt signaling pathway. Wnt is a well-known signaling pathway that is involved in cell growth, survival, and development.

Drug Interactions and Potential Therapies

FoxO3B is a potential drug target due to its unique structural features and its involvement in various cellular processes. There are several potential therapies that may target FoxO3B, including:

1. inhibitors of the Forkhead gene

Investigators have identified several potential inhibitors of the Forkhead gene that may target FoxO3B. These inhibitors have been shown to suppress the growth and survival of various cancer cell lines, including breast, lung, and ovarian cancer cells.

1. inhibitors of the FoxO3B gene

Investigators have identified several potential inhibitors of the FoxO3B gene that may target FoxO3B. These inhibitors have been shown to suppress the growth and survival of various cancer cell lines, including breast, lung, and ovarian cancer cells.

1. inhibitors of the FoxO3B-containing protein

Investigators have identified several potential inhibitors of the FoxO3B protein that may target FoxO3B. These inhibitors have been shown to suppress the growth and survival of various cancer cell lines, including breast, lung, and ovarian cancer cells.

Conclusion

FoxO3B is a pseudogene that encodes a protein involved in cell growth and survival. Its unique structural features and its involvement in various cellular processes make it a potential drug target. Several potential therapies have been identified that may target FoxO3B, including inhibitors of the Forkhead gene, the FoxO3B gene, and the FoxO3B-containing protein. Further research is needed to determine the efficacy and safety of these therapies in cancer treatment.

Protein Name: Forkhead Box O3B

Functions: Transcription factor

The "FOXO3B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FOXO3B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets